Inhaled Interferon-Beta for COPD Exacerbations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for COPD exacerbations exacerbated by viral infections in patients undergoing systemic corticosteroid therapy are inadequate, as systemic corticosteroids can inhibit interferon-beta (IFN-β) signaling, leading to compromised antiviral responses and worsened outcomes.
Innovation Solution
Inhaled interferon-beta (IFN-β) administration via nebulizer to directly target the lungs, overcoming corticosteroid-induced suppression of IFN-β production and enhancing antiviral defenses, thereby reducing virus-induced exacerbation severity and improving lung function in COPD patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If systemic corticosteroids are administered to treat COPD exacerbations, then inflammation is reduced and symptoms are improved, but interferon-beta signaling is inhibited and antiviral responses are compromised
Solution Approach 1:
The treatment is segmented into two distinct components: systemic corticosteroids for anti-inflammatory effects and inhaled interferon-beta for antiviral effects. This segmentation allows each treatment to target its specific function independently, avoiding the inhibitory interaction that occurs when interferon-beta signaling is blocked by systemic corticosteroids.
Solution Approach 2:
The patent introduces inhaled interferon-beta as an intermediary substance that directly acts on the lungs to enhance antiviral defenses. This intermediary bypasses the inhibitory effect of systemic corticosteroids by delivering the antiviral agent directly to the site of infection through inhalation, rather than relying on systemic distribution that would be blocked by corticosteroid-induced signaling inhibition.
2Reliability
If inhaled interferon-beta is administered to enhance antiviral responses, then lung antiviral defenses are boosted, but the treatment complexity increases when combined with systemic corticosteroids
Solution Approach 1:
The treatment regimen is segmented into separate administration routes and purposes: systemic corticosteroids for inflammation control and inhaled interferon-beta for antiviral protection. This segmentation, while adding a treatment component, organizes the therapy into distinct functional areas that can be managed independently.
Solution Approach 2:
Instead of trying to enhance interferon-beta signaling through systemic administration (which would be blocked by corticosteroids), the approach is inverted by using inhaled administration to deliver interferon-beta directly to the lungs. This inversion of the administration route bypasses the blocking mechanism and achieves the desired antiviral effect.
3Productivity
If systemic corticosteroids are used to treat exacerbations, then lung function improves in the short term, but antiviral biomarkers are suppressed and outcomes worsen
Solution Approach 1:
The inhaled interferon-beta acts as an intermediary that directly stimulates antiviral biomarker production in the lungs, counteracting the suppressive effect of systemic corticosteroids. This intermediary substance restores the antiviral defense mechanism that would otherwise be inhibited by the corticosteroid treatment.
Solution Approach 2:
The inhaled interferon-beta provides preliminary anti-action by pre-emptively counteracting the suppressive effect of systemic corticosteroids on antiviral biomarkers. By administering interferon-beta through inhalation, the treatment anticipates and neutralizes the harmful effect of corticosteroid-induced biomarker suppression before it can fully impact the antiviral response.
Data Source
AI summary
The present invention provides interferon-beta (IFN-β) for use in the treatment of virus-induced COPD exacerbations in patients treated with a systemic corticosteroid, wherein the IFN-β is administered by inhalation, e.g. by use of a nebuliser.